Integrative metabolic profile of myelodysplastic syndrome based on UHPLC-MS
© 2021 John Wiley & Sons, Ltd..
Myelodysplastic syndrome (MDS) is a neoplastic disease originating from hematopoietic stem cells. Currently, hematopoietic stem cell transplantation (HSCT) is the most effective cure, although lenalidomide, azacytidine, and decitabine have been applied to relieve symptoms of MDS. The purpose of this study was to evaluate the changes in endogenous metabolites by applying a UHPLC-MS (ultra-high-performance liquid chromatography-MS) metabolomics approach and to investigate metabolic pathways related to MDS. An untargeted metabolomics approach based on UHPLC-MS in combination with multivariate data analysis, including partial least squares discrimination analysis and orthogonal partial least squares discriminant analysis, was established to investigate potential biomarkers in the plasma of MDS patients. As a result, 29 biomarkers were identified to distinguish between MDS patients, HSCT patients, and healthy controls, which were mainly related to inflammation regulation, amino acid metabolism, fatty acid metabolism, and energy metabolism. To our knowledge, this is the first time where plasma metabolomics was combined with HSCT to study the pathogenesis and therapeutic target of MDS. The identification of biomarkers and analysis of metabolic pathways could offer the possibility of discovering new therapeutic targets for MDS in the future.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Biomedical chromatography : BMC - 35(2021), 9 vom: 30. Sept., Seite e5136 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yuan, Yunxia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Amino Acids |
|---|
| Anmerkungen: |
Date Completed 28.09.2021 Date Revised 28.09.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/bmc.5136 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM323993745 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323993745 | ||
| 003 | DE-627 | ||
| 005 | 20231225185350.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/bmc.5136 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1079.xml |
| 035 | |a (DE-627)NLM323993745 | ||
| 035 | |a (NLM)33844331 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yuan, Yunxia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Integrative metabolic profile of myelodysplastic syndrome based on UHPLC-MS |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.09.2021 | ||
| 500 | |a Date Revised 28.09.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 John Wiley & Sons, Ltd. | ||
| 520 | |a Myelodysplastic syndrome (MDS) is a neoplastic disease originating from hematopoietic stem cells. Currently, hematopoietic stem cell transplantation (HSCT) is the most effective cure, although lenalidomide, azacytidine, and decitabine have been applied to relieve symptoms of MDS. The purpose of this study was to evaluate the changes in endogenous metabolites by applying a UHPLC-MS (ultra-high-performance liquid chromatography-MS) metabolomics approach and to investigate metabolic pathways related to MDS. An untargeted metabolomics approach based on UHPLC-MS in combination with multivariate data analysis, including partial least squares discrimination analysis and orthogonal partial least squares discriminant analysis, was established to investigate potential biomarkers in the plasma of MDS patients. As a result, 29 biomarkers were identified to distinguish between MDS patients, HSCT patients, and healthy controls, which were mainly related to inflammation regulation, amino acid metabolism, fatty acid metabolism, and energy metabolism. To our knowledge, this is the first time where plasma metabolomics was combined with HSCT to study the pathogenesis and therapeutic target of MDS. The identification of biomarkers and analysis of metabolic pathways could offer the possibility of discovering new therapeutic targets for MDS in the future | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a UHPLC-MS | |
| 650 | 4 | |a biomarkers | |
| 650 | 4 | |a metabolic pathways | |
| 650 | 4 | |a metabolomics | |
| 650 | 4 | |a myelodysplastic syndrome | |
| 650 | 7 | |a Amino Acids |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Fatty Acids |2 NLM | |
| 700 | 1 | |a Zhao, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Taifeng |e verfasserin |4 aut | |
| 700 | 1 | |a Ji, Zhengchao |e verfasserin |4 aut | |
| 700 | 1 | |a Xin, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Siyao |e verfasserin |4 aut | |
| 700 | 1 | |a Qin, Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Longshan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomedical chromatography : BMC |d 1987 |g 35(2021), 9 vom: 30. Sept., Seite e5136 |w (DE-627)NLM012669806 |x 1099-0801 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2021 |g number:9 |g day:30 |g month:09 |g pages:e5136 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/bmc.5136 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2021 |e 9 |b 30 |c 09 |h e5136 | ||